Editor's Corner

  • Novartis CEO: We can rebuild our good name after 'reputational hit' in Japan

    What's going to save Novartis' reputation in Japan? Science, says CEO Joe Jimenez, a week after the government suspended his Japanese unit for failure to report side effects. In an interview with the Japanese news service Nikkei, Jimenez admitted that Novartis took "a reputational hit" in Japan as a high-profile trial data scandal unfolded. Its brand may be tarnished in the country, but the Swiss drugmaker can regain its good name there, the CEO insists.

To avoid becoming deal bait, Mylan CEO may have to make another big buy

It's been less than a week since Mylan completed its deal with Abbott, scooping up a large chunk of the Illinois company's overseas generics business. But CEO Heather Bresch is already hinting at another big transaction.

Genentech's cancer drug supply switch costs more, delays treatment, survey finds

Top hospitals are still irate about Genentech's decision to move its best-selling cancer drugs to specialty distributors. And they're not giving up on persuading the company to change back.

Merck's Rebif held its own in last year's MS market shakeup. What about 2015?

With oral rivals lurking for Rebif, the leading drug from Merck KGaA, the good news for the German pharma is that the news isn't that bad.

Gilead's hep C combo Harvoni wins NICE blessing at $58K price

The U.K.'s cost-effectiveness watchdogs gave a thumbs up to Gilead Sciences' combo hepatitis C pill Harvoni, despite its £39,000 price, or about $58,000. The pill combines Gilead's new blockbuster hep C drug Sovaldi with another antiviral, ledipasvir, and has delivered impressive cure rates.

Sanofi's fight for Toujeo market share won't be easy, analysts say

Sanofi has its second diabetes approval in as many months: Toujeo, its long-acting follow-up to the megablockbuster Lantus. It's a big moment for the French drugmaker and its diabetes franchise, which needs the new drugs to perform, and quickly, to cushion the blow from forthcoming Lantus biosimilars.


From Our Sister Sites


Women with dense breasts are more likely to have so-called mammographically occult breast cancer, meaning the disease won't be detected using a conventional mammogram, data presented at the San Antonio Breast Cancer Symposium showed.


Becton Dickinson has acquired Crisi Medical Systems for an undisclosed sum. The San Diego, CA-based startup is the only provider of real-time drug identification, dose measurement and allergy detection data for manual IV bolus injections that wirelessly populates patient electronic medical records, according to BD.